Ahmad A. Tarhini

15.0k total citations · 1 hit paper
276 papers, 8.0k citations indexed

About

Ahmad A. Tarhini is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Ahmad A. Tarhini has authored 276 papers receiving a total of 8.0k indexed citations (citations by other indexed papers that have themselves been cited), including 225 papers in Oncology, 115 papers in Immunology and 95 papers in Molecular Biology. Recurrent topics in Ahmad A. Tarhini's work include Cancer Immunotherapy and Biomarkers (128 papers), CAR-T cell therapy research (113 papers) and Immunotherapy and Immune Responses (98 papers). Ahmad A. Tarhini is often cited by papers focused on Cancer Immunotherapy and Biomarkers (128 papers), CAR-T cell therapy research (113 papers) and Immunotherapy and Immune Responses (98 papers). Ahmad A. Tarhini collaborates with scholars based in United States, Australia and France. Ahmad A. Tarhini's co-authors include John M. Kirkwood, Lisa H. Butterfield, Sanjiv S. Agarwala, Cindy Sander, Helen Gogas, Yan Lin, Hassane M. Zarour, Theofanis Floros, Hussein A. Tawbi and Michael B. Atkins and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ahmad A. Tarhini

260 papers receiving 7.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

2016 813 citations Ahmad A. Tarhini et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ahmad A. Tarhini United States	46	5.6k	3.6k	2.4k	1.2k	546	276	8.0k
Evan J. Lipson United States	41	5.9k 1.0×	2.2k 0.6×	1.4k 0.6×	1.6k 1.3×	532 1.0×	126	7.7k
Michel Obéid Switzerland	22	4.2k 0.7×	3.5k 1.0×	1.5k 0.6×	1.1k 0.9×	314 0.6×	41	7.4k
René González United States	48	6.6k 1.2×	2.6k 0.7×	4.4k 1.8×	1.2k 0.9×	284 0.5×	189	9.2k
Paola Queirolo Italy	44	5.3k 0.9×	2.5k 0.7×	3.0k 1.2×	951 0.8×	237 0.4×	233	7.3k
Steinar Aamdal Norway	39	4.1k 0.7×	2.4k 0.7×	3.0k 1.2×	1.1k 0.9×	313 0.6×	130	6.6k
Jacob Schachter Israel	47	6.5k 1.2×	3.0k 0.8×	3.0k 1.2×	857 0.7×	220 0.4×	189	8.4k
Stefan Suciu Belgium	54	4.7k 0.8×	2.4k 0.7×	3.5k 1.4×	777 0.6×	835 1.5×	235	9.5k
Sanjiv S. Agarwala United States	48	6.1k 1.1×	2.5k 0.7×	4.2k 1.8×	1.9k 1.5×	675 1.2×	209	9.7k
Vanna Chiarion‐Sileni Italy	51	7.3k 1.3×	3.1k 0.9×	4.1k 1.7×	2.2k 1.8×	443 0.8×	244	10.4k
Gabriel Sica United States	38	4.0k 0.7×	3.0k 0.8×	2.0k 0.8×	1.3k 1.0×	160 0.3×	97	6.9k

Countries citing papers authored by Ahmad A. Tarhini

Since Specialization

Citations

This map shows the geographic impact of Ahmad A. Tarhini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ahmad A. Tarhini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ahmad A. Tarhini more than expected).

Fields of papers citing papers by Ahmad A. Tarhini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ahmad A. Tarhini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ahmad A. Tarhini. The network helps show where Ahmad A. Tarhini may publish in the future.

Co-authorship network of co-authors of Ahmad A. Tarhini

This figure shows the co-authorship network connecting the top 25 collaborators of Ahmad A. Tarhini. A scholar is included among the top collaborators of Ahmad A. Tarhini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ahmad A. Tarhini. Ahmad A. Tarhini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Boucher, Justin C., Elena V. Kostenko, Ahmad A. Tarhini, et al.. (2025). Effector T cells under hypoxia have an altered transcriptome similar to tumor-stressed T cells found in non-responsive melanoma patients. Journal for ImmunoTherapy of Cancer. 13(2). e010153–e010153. 1 indexed citations

Tarhini, Ahmad A., Sandra J. Lee, William A. LaFramboise, et al.. (2025). Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma. Clinical Cancer Research. 31(15). 3249–3258.

Khushalani, Nikhil I., Ghassan El‐Haddad, Kenneth L. Gage, et al.. (2024). First-in-human study of ²²⁵actinium mti-201 (²²⁵Ac-MTI-201) in metastatic uveal melanoma (UM).. Journal of Clinical Oncology. 42(16_suppl). TPS9612–TPS9612. 1 indexed citations

Vaishampayan, Ulka N., Randy F. Sweis, Deepak Kilari, et al.. (2024). Phase 1 study (DRAGON) of SRK-181 (linavonkibart), a latent TGFβ1 inhibitor, combined with pembrolizumab in patients with anti-PD1 resistant advanced solid tumors: Updated results of expansion part.. Journal of Clinical Oncology. 42(16_suppl). 2507–2507. 1 indexed citations

Brohl, Andrew S., Ann W. Silk, Jacob Thomas, et al.. (2024). Phase 1b trial of IFx-Hu2.0, a novel in situ cancer vaccine, in checkpoint inhibitor-resistant Merkel cell carcinoma (MCC) and cutaneous squamous cell carcinoma (cSCC).. Journal of Clinical Oncology. 42(16_suppl). 9592–9592. 1 indexed citations

Eroglu, Zeynep, Joseph Markowitz, Lilit Karapetyan, et al.. (2024). Durability of immune checkpoint inhibitor (ICI) response following treatment discontinuation in advanced merkel cell carcinoma (MCC).. Journal of Clinical Oncology. 42(16_suppl). 9596–9596.

Brohl, Andrew S., Joseph Markowitz, Zeynep Eroglu, et al.. (2023). Phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant merkel cell carcinoma and cutaneous squamous cell carcinoma.. Journal of Clinical Oncology. 41(16_suppl). 9534–9534. 6 indexed citations

Wang, Xuefeng, Vineeth Sukrithan, Aakrosh Ratan, et al.. (2023). Incorporating long non-coding RNA (lncRNA) into genome-wide biomarker screening for prognostic gene signatures of immunotherapy outcomes.. Journal of Clinical Oncology. 41(16_suppl). 2617–2617. 2 indexed citations

Marin‐Acevedo, Julian A., Youngchul Kim, Andrew S. Brohl, et al.. (2023). Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma. Cancers. 15(12). 3180–3180. 14 indexed citations

10.

LaFramboise, William A., et al.. (2023). A Tumor and Immune-Related Micro-RNA Signature Predicts Relapse-Free Survival of Melanoma Patients Treated with Ipilimumab. International Journal of Molecular Sciences. 24(9). 8167–8167. 4 indexed citations

11.

Tarhini, Ahmad A., Karmela K Chan, David F. McDermott, et al.. (2021). A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆. ESMO Open. 6(2). 100050–100050. 12 indexed citations

12.

Butterfield, Lisa H., Fengmin Zhao, Charles Lee, et al.. (2017). Immune Correlates of GM-CSF and Melanoma Peptide Vaccination in a Randomized Trial for the Adjuvant Therapy of Resected High-Risk Melanoma (E4697). Clinical Cancer Research. 23(17). 5034–5043. 35 indexed citations

13.

Tarhini, Ahmad A., Haris Zahoor, Jennifer H. Yearley, et al.. (2015). Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma. Journal of Translational Medicine. 13(1). 319–319. 27 indexed citations

14.

Tarhini, Ahmad A.. (2014). Adjuvant Therapy for High-Risk Melanoma. 10(5). 1 indexed citations

15.

Fourcade, Julien, Zhaojun Sun, Ornella Pagliano, et al.. (2013). PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen–Specific CD8+ T Cells Induced by Melanoma Vaccines. Cancer Research. 74(4). 1045–1055. 175 indexed citations

16.

Go, Ronald S., Sandra J. Lee, Donghoon Shin, et al.. (2013). ECOG Phase II Trial of Graded-Dose Peginterferon α-2b in Patients with Metastatic Melanoma Overexpressing Basic Fibroblast Growth Factor (E2602). Clinical Cancer Research. 19(23). 6597–6604. 7 indexed citations

17.

Kirkwood, John M., Lisa H. Butterfield, Ahmad A. Tarhini, et al.. (2012). Immunotherapy of cancer in 2012. CA A Cancer Journal for Clinicians. 62(5). 309–335. 345 indexed citations

18.

Tarhini, Ahmad A., Paul Frankel, Kim Margolin, et al.. (2011). Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin. Clinical Cancer Research. 17(20). 6574–6581. 62 indexed citations

19.

Krauze, Michal T., Ahmad A. Tarhini, Helen Gogas, & John M. Kirkwood. (2011). Prognostic significance of autoimmunity during treatment of melanoma with interferon. Seminars in Immunopathology. 33(4). 385–391. 223 indexed citations

20.

Tarhini, Ahmad A., Ernest Lo, & David R. Minor. (2010). Releasing the Brake on the Immune System: Ipilimumab in Melanoma and Other Tumors. Cancer Biotherapy and Radiopharmaceuticals. 25(6). 601–613. 114 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact